WO2018088570A1 - 皮膚外用剤組成物 - Google Patents
皮膚外用剤組成物 Download PDFInfo
- Publication number
- WO2018088570A1 WO2018088570A1 PCT/JP2017/040974 JP2017040974W WO2018088570A1 WO 2018088570 A1 WO2018088570 A1 WO 2018088570A1 JP 2017040974 W JP2017040974 W JP 2017040974W WO 2018088570 A1 WO2018088570 A1 WO 2018088570A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mass
- surfactant
- silicone elastomer
- composition
- less
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/895—Polysiloxanes containing silicon bound to unsaturated aliphatic groups, e.g. vinyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
- A61K8/894—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone modified by a polyoxyalkylene group, e.g. cetyl dimethicone copolyol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/54—Polymers characterized by specific structures/properties
- A61K2800/542—Polymers characterized by specific structures/properties characterized by the charge
- A61K2800/5422—Polymers characterized by specific structures/properties characterized by the charge nonionic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/54—Polymers characterized by specific structures/properties
- A61K2800/542—Polymers characterized by specific structures/properties characterized by the charge
- A61K2800/5428—Polymers characterized by specific structures/properties characterized by the charge amphoteric or zwitterionic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/596—Mixtures of surface active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
Definitions
- the cross-linked organopolysiloxane having a polyglycerin moiety in the cross-linked structure described in Patent Document 2 can be expressed as an emulsified silicone elastomer.
- the emulsified silicone elastomer is contained in the external preparation for skin, stickiness occurs when the composition is applied to the skin, and the user cannot obtain a smooth feeling of use.
- compositions for external use on the skin that is fresh and non-sticky when applied to the skin and can provide a smooth feeling of use.
- the external composition for skin comprises 0.1% by mass to 8% by mass of a non-emulsifying silicone elastomer, a polyether-modified silicone surfactant, and a hydrophilic nonionic surfactant. And containing.
- the hydrophilic nonionic surfactant includes a glycerin derivative type surfactant.
- the polyether-modified silicone surfactant is 0.3 parts by mass or more with respect to 1 part by mass of the silicone elastomer.
- a hydrophilic nonionic surfactant is 0.2 mass part or more with respect to 1 mass part of silicone elastomer.
- the amphoteric surfactant When the amphoteric surfactant is contained, the amphoteric surfactant is 1.5 parts by mass or less with respect to 1 part by mass of the glycerin derivative-type surfactant.
- the viscosity of the composition is 9,500 mPa ⁇ s or less.
- the composition for external use of skin contains 0.1% by mass to 8% by mass of a non-emulsifying silicone elastomer, a polyether-modified silicone surfactant, and an amphoteric surfactant.
- the polyether-modified silicone surfactant is 0.3 parts by mass or more with respect to 1 part by mass of the silicone elastomer.
- An amphoteric surfactant is 0.65 mass part or more with respect to 1 mass part of silicone elastomer.
- the amount of the glycerin derivative type surfactant is less than 0.2 parts by mass relative to 1 part by mass of the amphoteric surfactant.
- the viscosity of the composition is 9,500 mPa ⁇ s or less.
- the silicone elastomer can be suppressed and the silicone elastomer can be uniformly dispersed. Thereby, both the smooth and elegant feeling of use by the silicone elastomer and the fresh feeling of use can be realized.
- the external composition for skin contains an amphoteric surfactant.
- the amphoteric surfactant is 0.15 to 1.5 parts by mass with respect to 1 part by mass of the glycerin derivative-type surfactant.
- the amphoteric surfactant contains lauryldimethylamide acetic acid betaine.
- the polyether-modified silicone surfactant has a structure in which a plurality of hydrophilic groups having polyether groups are grafted from the main chain.
- the main chain includes a silicone chain.
- the polyether-modified silicone surfactant contains a polyoxyethylene methyl polysiloxane copolymer.
- the glycerin derivative-type surfactant contains a polyoxyethylene glycerin fatty acid ester.
- the hydrophilic nonionic surfactant further includes a sorbitan derivative type surfactant.
- the sorbitan derivative type surfactant is 0.5 to 5 parts by mass with respect to 1 part by mass of the glycerin derivative type surfactant.
- the external composition for skin further contains silicone oil.
- the average particle size of the silicone elastomer is 100 ⁇ m or less.
- the composition for external use on the skin is a polymer and / or copolymer (crosslinked polymer) having 2-acrylamido-2-propanesulfonic acid or a salt thereof as a structural unit.
- crosslinked polymer having 2-acrylamido-2-propanesulfonic acid or a salt thereof as a structural unit.
- the content of the silicone elastomer is 5% by mass or less based on the mass of the composition.
- the polyether-modified silicone surfactant is 0.5 parts by mass or more with respect to 1 part by mass of the silicone elastomer.
- the silicone elastomer is a crosslinked organopolysiloxane having no polyoxyalkylene group.
- the silicone elastomer has a form of irregularly shaped particles.
- POE is an abbreviation for polyoxyethylene and POP is an abbreviation for polyoxypropylene, and the numbers in parentheses after POE or POP represent the average number of moles of POE groups or POP groups in the compound.
- the “substantial amount” refers to an amount that can produce an effect by adding the compound.
- the aggregation of the silicone elastomer means that the silicone elastomer moves in the composition to cause aggregation and cannot be uniformly dispersed in the composition. For example, when the silicone elastomer particles are united and the particle size is increased, the dispersibility is lowered and the appearance is not smooth.
- the external composition for skin according to the first to fourth embodiments contains (A) a silicone elastomer, (B) a silicone surfactant, and (C) a hydrophilic surfactant.
- silicone elastomer applicable to the composition of the present disclosure is not particularly limited as long as it can be applied to the skin.
- silicone elastomers include dimethicone cross polymer, dimethicone / vinyl dimethicone cross polymer, dimethicone / phenyl vinyl dimethicone cross polymer, vinyl dimethicone / lauryl dimethicone cross polymer, lauryl polydimethylsiloxyethyl dimethicone / bis-vinyl dimethicone cross polymer, alkyl ( C30-45) cetearyl dimethicone crosspolymer, cetearyl dimethicone crosspolymer and the like.
- dimethicone / vinyl dimethicone crosspolymer which is also referred to as polysilicon-11, is preferable from the viewpoint of non-aggregation property of the silicone elastomer.
- the silicone elastomer is present in a granular form (as particles).
- the average particle size of the silicone elastomer particles is preferably 150 ⁇ m or less, and more preferably 100 ⁇ m or less. When the average particle size is larger than 150 ⁇ m, the dispersibility of the silicone elastomer is lowered and the uniformity is lost.
- silicone surfactant for example, polyoxyethylene methylpolysiloxane copolymer, cetyl dimethicone copolyol, and the like can be used.
- examples of commercially available polyoxyethylene methylpolysiloxane copolymers include PEG-10 dimethicone (silicone KF-6017P, Shin-Etsu Chemical Co., Ltd.), cetyl PEG / PPG10-1 dimethicone (ABIL (registered trademark) EM90, EVONIK) And the like.
- the content of the silicone surfactant in the composition of the present disclosure is preferably 0.3% by mass or more, more preferably 0.5% by mass or more, and 0.8% by mass with respect to the mass of the composition. More preferably, it is more preferably 1% by mass or more. If the content of the silicone surfactant is less than 0.3% by mass, the dispersibility of the silicone elastomer is lowered.
- the content of the silicone surfactant in the composition of the present disclosure may be 5% by mass or less, 4% by mass or less, or 3% by mass or less with respect to the mass of the composition.
- the content of the silicone surfactant is preferably 2.5% by mass or less, more preferably 2% by mass or less, and further preferably 1.5% by mass or less with respect to the mass of the composition. If the content of the silicone surfactant exceeds 5% by mass, the emulsion stability is lowered.
- hydrophilic surfactant a nonionic surfactant and / or an amphoteric surfactant can be used.
- the mass ratio of (A) silicone elastomer and (C) hydrophilic surfactant in the composition of the present disclosure is that the mass of (A) is 0.2 or more when the mass of (C) is 1. Preferably, it is 0.3 or more, more preferably 0.5 or more.
- the mass ratio of (A) silicone elastomer to (C) hydrophilic surfactant is preferably 3 or less, and preferably 2 or less when the mass of (C) is 1. And more preferably 1.5 or less. When the mass ratio is within this range, aggregation of the silicone elastomer can be suppressed.
- hydrophilic nonionic surfactants examples include POE-sorbitan fatty acid esters (eg, POE-sorbitan monooleate, POE-sorbitan monostearate, POE-sorbitan monooleate, POE-sorbitan tetraoleate, etc.); POE-sorbite fatty acid ester (eg POE-sorbite monolaurate, POE-sorbite monooleate, POE-sorbite pentaoleate, POE-sorbite monostearate, etc.); POE-glycerin fatty acid ester (eg POE-glycerin monoester) POE-monooleate such as stearate, POE-glycerin monoisostearate, POE-glycerin triisostearate, etc .; POE-fatty acid esters (eg POE-distearate, POE- Nodiolate, ethylene glycol distearate, POE-sorbitan monoo
- the hydrophilic nonionic surfactant can be used in combination with a plurality of surfactants.
- the nonionic surfactant can include at least one of a sorbitan derivative-type surfactant and a glycerin derivative-type surfactant.
- polyoxyethylene sorbitan fatty acid ester for example, polyoxyethylene sorbitan fatty acid ester and the like can be used.
- examples of commercially available products of polyoxyethylene sorbitan fatty acid ester include POE (20) sorbitan cocoate (NIKKOL (registered trademark) TL-10, Nikko Chemicals).
- sorbitan derivative type surfactant examples include, for example, sorbitan laurate ((NIKKOL (registered trademark) SL-10 and LM, Nikko Chemicals); (emazole (registered trademark) 110, Kao)), palmitic Sorbitan acid (NIKKOL (registered trademark) SP-10, Nikko Chemicals), sorbitan oleate (NIKKOL (registered trademark) SO-10V, Nikko Chemicals), sorbitan stearate (NIKKOL (registered trademark) SS-10, Nikko Chemicals) ), Sorbitan isostearate (NIKKOL (registered trademark) SI-10PKV, Nikko Chemicals), sorbitan sesquioleate ((NIKKOL (registered trademark) SO-15, Nikko Chemicals)); (Leodol (registered trademark) AO-15) , Kao); (NOFAB E (registered trademark) SO-852S, NOF Corporation)), sorbitan la
- glycerin derivative-type surfactant for example, polyoxyethylene glycerin fatty acid ester (polyoxyethylene fatty acid glyceryl), self-emulsifying glycerin fatty acid ester, alkyl glyceryl ether and the like can be used.
- polyoxyethylene glyceryl isostearate can be used as the glycerin derivative-type surfactant.
- polyoxyethylene glyceryl isostearate examples include PEG-60 glyceryl isostearate (EMALEX (registered trademark) GWIS160N, Nippon Emulsion).
- the HLB of the nonionic surfactant calculated by the Davis method is preferably 10 or more, more preferably 12 or more, and even more preferably 14 or more.
- the effect which suppresses aggregation of a silicone elastomer will fall that HLB is less than 10.
- the content of the nonionic surfactant in the composition of the present disclosure is preferably 0.1% by mass or more, more preferably 0.3% by mass or more with respect to the mass of the composition, More preferably, it is at least 1% by mass, and even more preferably at least 1% by mass.
- the content rate of a nonionic surfactant can be 3 mass% or less, 2.5 mass% or less, and / or 1.5 mass% or less with respect to the mass of a composition, for example.
- the content is calculated by the total mass of the nonionic surfactants.
- the mass ratio of the sorbitan derivative type surfactant to the glycerin derivative type surfactant is the mass of the glycerin derivative type surfactant.
- the mass of the sorbitan derivative-type surfactant is more preferably 0.5 or more, more preferably 1 or more, more preferably 1.3 or more, and further more preferably 2 or more. preferable.
- the mass ratio of the sorbitan derivative type surfactant and the glycerin derivative type surfactant is more preferably 4 or less when the mass of the glycerin derivative type surfactant is 1, It is more preferable that it is 3.5 or less.
- the nonionic surfactant is preferably a glycerin derivative type surfactant, and the glycerin derivative type surfactant and the sorbitan derivative type interface are used. More preferably, it is combined with an activator.
- the glycerin derivative-type surfactant has a higher aggregation suppressing effect on the (A) silicone elastomer than the sorbitan derivative-type surfactant. When the glycerin derivative type surfactant and the sorbitan derivative type surfactant are combined, the aggregation suppressing effect of the (A) silicone elastomer can be further enhanced.
- the mass ratio of (A) silicone elastomer and (C1) nonionic surfactant in the composition of the present disclosure is that the mass of (A) is 0.2 or more when the mass of (C1) is 1. Preferably, it is 0.3 or more, more preferably 0.5 or more.
- the mass ratio of (A) silicone elastomer to (C1) nonionic surfactant is preferably 3 or less when the mass of (C1) is 1, and is 2 or less. More preferably, it is more preferably 1.5 or less. When the mass ratio is within this range, aggregation of the silicone elastomer can be suppressed.
- the content of the (C1) nonionic surfactant in the composition of the present disclosure is preferably set according to each embodiment described later.
- the content of (C1) nonionic surfactant is preferably determined in relation to the content of (C2) amphoteric surfactant.
- the (C1) nonionic surfactant may not be added depending on the content of the (C2) amphoteric surfactant.
- (C1) nonionic surfactant and “(B) silicone surfactant” are different surfactants, and “(C1) nonionic surfactant” referred to in the present disclosure.
- the “agent” does not include the above-mentioned “(B) silicone surfactant”.
- amphoteric surfactants examples include lauryldimethylaminoacetic acid betaine (Nissan Anone (registered trademark) BL-SF, NOF Corporation).
- composition of this indication can further contain (D) silicone oil in addition to the said component.
- the content of the silicone oil in the composition of the present disclosure is preferably 7% by mass or more, more preferably 8% by mass or more, and further preferably 9% by mass or more with respect to the mass of the composition.
- the dispersibility of a silicone elastomer can be improved as the content rate of a silicone oil is 7 mass% or more.
- the content of the silicone oil is preferably 16% by mass or less, more preferably 15% by mass or less, and still more preferably 14% by mass or less with respect to the mass of the composition. If the content of the silicone oil exceeds 16% by mass, the emulsion stability is lowered.
- composition of this indication can further contain (E) thickener in addition to the said component.
- a taurate synthetic polymer and / or an acrylate synthetic polymer can be used as the thickener.
- a taurate polymer thickener a polymer and / or copolymer (crosslinking) having 2-acrylamido-2-propanesulfonic acid (acryloyldimethyltauric acid) or a salt thereof (AMPS structure) as a structural unit.
- a thickener examples include (acryloyldimethyltaurine ammonium / behenes methacrylate-25) crosspolymer (Aristoflex (registered trademark) HMB, Clariant Japan), (acryloyldimethyltaurine ammonium / vinylpyrrolidone) copolymer (Aristoflex).
- thickener can be added as long as the effects of the present invention are not impaired.
- Other thickeners include, for example, gum arabic, carrageenan, gum karaya, gum tragacanth, carob gum, quince seed (malmello), casein, dextrin, gelatin, sodium pectate, sodium alginate, methylcellulose, ethylcellulose, carboxymethylcellulose (CMC).
- PVA polyvinyl alcohol
- PVM polyvinyl methyl ether
- PVP polyvinyl pyrrolidone
- sodium polyacrylate carboxyvinyl polymer
- locust bean gum locust bean gum
- guar gum tamarind gum
- dialkyldimethylammonium cellulose sulfate Xanthan gum
- magnesium aluminum silicate bentonite
- the cosmetic composition of the present disclosure has other components such as an aqueous solvent, an anionic surfactant, a cationic surfactant, a lipophilic nonionic surfactant, and a powder as long as the effects of the present disclosure are not impaired.
- Moisturizer, water-soluble polymer, thickener, oil component, film agent, UV absorber, sequestering agent, amino acid, organic amine, polymer emulsion, pH adjuster, skin nutrient, vitamin, antioxidant Antioxidant aids, fragrances and the like can be appropriately contained as necessary.
- water used for cosmetics, quasi-drugs and the like can be used.
- purified water, ion-exchanged water, tap water and the like can be used.
- the aqueous phase can further contain a water-soluble alcohol depending on the purpose.
- water-soluble alcohols include lower alcohols, polyhydric alcohols, polyhydric alcohol polymers, divalent alcohol alkyl ethers, dihydric alcohol alkyl ethers, dihydric alcohol ether esters, glycerin monoalkyl ethers, sugar alcohols, Examples thereof include at least one selected from monosaccharides, oligosaccharides, polysaccharides and derivatives thereof.
- polyhydric alcohol examples include divalent alcohols (for example, ethylene glycol, propylene glycol, trimethylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, tetramethylene glycol, 2,3-butylene glycol, Pentamethylene glycol, 2-butene-1,4-diol, hexylene glycol, octylene glycol, etc.); trivalent alcohol (eg, glycerin, trimethylolpropane, etc.); tetravalent alcohol (eg, 1, 2, 6) Pentaerythritol, such as hexanetriol, etc .; pentavalent alcohol (eg, xylitol, etc.); hexavalent alcohol (eg, sorbitol, mannitol, etc.); polyhydric alcohol polymer (eg, diethylene glycol, dipropylene glycol, Ethylene glycol, polypropylene glycol, tetraethylene glycol,
- oligosaccharide for example, at least one selected from sucrose, gnocyanose, umbelliferose, lactose, planteose, isoliquinoses, ⁇ , ⁇ -trehalose, raffinose, lycnose, umbilicin, stachyose berbasose, etc. Can be mentioned.
- polysaccharide examples include cellulose, quince seed, chondroitin sulfate, starch, galactan, dermatan sulfate, glycogen, gum arabic, heparan sulfate, hyaluronic acid, tragacanth gum, keratan sulfate, chondroitin, xanthan gum, mucoitin sulfate, guar gum, dextran, kerato sulfate. And at least one selected from locust bean gum, succinoglucan, and caronic acid.
- Examples of other polyols include at least one selected from polyoxyethylene methyl glucoside (Glucam E-10), polyoxypropylene methyl glucoside (Glucam P-10) and the like.
- Examples of the cationic surfactant include alkyltrimethylammonium salts (eg, stearyltrimethylammonium chloride, lauryltrimethylammonium chloride, etc.); alkylpyridinium salts (eg, cetylpyridinium chloride, etc.); distearyldimethylammonium dialkyldimethylammonium chloride; Poly (N, N′-dimethyl-3,5-methylenepiperidinium chloride); alkyl quaternary ammonium salt; alkyldimethylbenzylammonium salt; alkylisoquinolinium salt; dialkyl morpholinium salt; POE-alkylamine; Examples include alkylamine salts; polyamine fatty acid derivatives; amyl alcohol fatty acid derivatives; benzalkonium chloride; benzethonium chloride and the like.
- alkyltrimethylammonium salts eg, stearyltrimethylammonium chloride, lauryltrimethyl
- lipophilic nonionic surfactant examples include sorbitan fatty acid esters (for example, sorbitan monooleate, sorbitan monoisostearate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesquioleate, sorbitan Trioleate, penta-2-ethylhexyl diglycerol sorbitan, tetra-2-ethylhexyl diglycerol sorbitan, etc.); glycerin polyglycerin fatty acid (eg mono cottonseed oil fatty acid glycerin, monoerucic acid glycerin, sesquioleate glycerin, glyceryl monostearate) , ⁇ , ⁇ '-oleic acid pyroglutamate glycerin, monostearate glycerin malate, etc.); propylene glycol fatty acid esters (eg mono
- the term “powder” used in this specification is synonymous with “powder”.
- the powder is not particularly limited as long as it can be generally used for cosmetics and the like.
- examples of the powder include inorganic powders (for example, talc, kaolin, mica, sericite (sericite), muscovite, phlogopite, synthetic mica, red mica, biotite, lithia mica, calcined mica, calcined talc, permiculite, Magnesium carbonate, calcium carbonate, aluminum silicate, barium silicate, calcium silicate, magnesium silicate, strontium silicate, metal tungstate, magnesium, silica, zeolite, glass, barium sulfate, calcined calcium sulfate (baked gypsum), Calcium phosphate, fluorapatite, hydroxyapatite, ceramic powder, metal soap (eg, zinc myristate, calcium palmitate, aluminum stearate), boron
- hydrocarbon oil examples include liquid paraffin, ozokerite, squalane, pristane, paraffin, ceresin, squalene, petrolatum, and microcrystalline wax.
- Salicylic acid-based ultraviolet absorbers eg, amyl salicylate, menthyl salicylate, homomenthyl salicylate, octyl salicylate, phenyl salicylate, benzyl salicylate, p-isopropanol phenyl salicylate
- cinnamic acid-based ultraviolet absorbers For example, octylmethoxycinnamate, ethyl-4-isopropylcinnamate, methyl-2,5-diisopropylcinnamate, ethyl-2,4-diisopropylcinnamate, methyl-2,4-diisopropylcinnamate, propyl-p-methoxy Cinnamate, isopropyl-
- sequestering agent examples include 1-hydroxyethane-1,1-diphosphonic acid, 1-hydroxyethane-1,1-diphosphonic acid tetrasodium salt, disodium edetate, trisodium edetate, and tetrasodium edetate.
- polymer emulsion examples include acrylic resin emulsion, polyethyl acrylate emulsion, acrylic resin liquid, polyacryl alkyl ester emulsion, polyvinyl acetate resin emulsion, natural rubber latex, and the like.
- pH adjuster examples include buffers such as lactic acid-sodium lactate, citric acid-sodium citrate, and succinic acid-sodium succinate.
- vitamins examples include vitamins A, B1, B2, B3, B6, C, E and derivatives thereof, pantothenic acid and derivatives thereof, and biotin.
- antioxidants examples include tocopherols, dibutylhydroxytoluene, butylhydroxyanisole, gallic acid esters and the like.
- antioxidant assistant examples include phosphoric acid, citric acid, ascorbic acid, maleic acid, malonic acid, succinic acid, fumaric acid, kephalin, hexametaphosphate, phytic acid, ethylenediaminetetraacetic acid and the like.
- ingredients that can be blended include, for example, preservatives (ethyl paraben, butyl paraben, chlorphenesin, phenoxyethanol, etc.); anti-inflammatory agents (eg, glycyrrhizic acid derivatives, glycyrrhetinic acid derivatives, salicylic acid derivatives, hinokitiol, zinc oxide, allantoin, etc.
- preservatives ethyl paraben, butyl paraben, chlorphenesin, phenoxyethanol, etc.
- anti-inflammatory agents eg, glycyrrhizic acid derivatives, glycyrrhetinic acid derivatives, salicylic acid derivatives, hinokitiol, zinc oxide, allantoin, etc.
- Whitening agent for example, placenta extract, saxifrage extract, arbutin, etc.
- various extracts for example, Isaiyobara extract, Oubak, Ouren, Shikon, licorice, Peonies, assembly, birch, sage, loquat, carrot, aloe , Okra, mallow, iris, grape, yokuinin, tencha, loofah, lily, cherry leaf, saffron, nematode, ginger, hypericum, onionis, garlic, pepper, chimpi, touki, ryocha, seaweed, yeast, etc.), Active agent (for example, royal jelly, photosensitizer, cholesterol derivative, etc.); blood circulation promoter (for example, nonyl acid valenyl amide, nicotinic acid benzyl ester, nicotinic acid ⁇ -butoxyethyl ester, capsaicin, gingerone, cantharis tincture, e
- composition of the present disclosure includes caffeine, tannin, verapamil, tranexamic acid and derivatives thereof, various herbal extracts such as licorice, karin, and yew, etc., tocopherol acetate, glycyrrhizic acid, glycyrrhizic acid and derivatives or salts thereof, etc.
- Drugs, vitamin C, magnesium ascorbate phosphate, glucoside ascorbate, whitening agents such as arbutin and kojic acid, amino acids such as arginine and lysine, and derivatives thereof can also be contained as appropriate.
- the viscosity of the composition of the present disclosure is preferably less than 10,000 mPa ⁇ s, more preferably 9,500 mPa ⁇ s or less, more preferably 9,000 mPa ⁇ s or less, and 8,000 mPa ⁇ s or less. More preferably, it is 7,000 mPa ⁇ s or less, more preferably 6,000 mPa ⁇ s or less, and further preferably 5,000 mPa ⁇ s or less.
- the viscosity By setting the viscosity to less than 10,000 mPa ⁇ s, the user can obtain a fresh feel.
- the viscosity of the composition of the present disclosure is preferably 2,000 mPa ⁇ s or more, more preferably 3,000 mPa ⁇ s or more, and further preferably 4,000 mPa ⁇ s or more. If the viscosity is less than 2,000 mPa ⁇ s, it becomes too watery.
- the viscosity can be measured at 30 ° C. with a BL type viscometer (No. 3 rotor, rotation speed: 12 rpm).
- the content of the glycerin derivative-type surfactant is preferably 0.2% by mass or more, and more preferably 0.4% by mass or more with respect to the mass of the composition. When the content of the glycerin derivative-type surfactant is less than 0.2% by mass, the stability of the silicone elastomer is lowered.
- the content of the glycerin derivative-type surfactant is preferably 5% by mass or less, more preferably 4% by mass or less, and further preferably 3% by mass or less with respect to the mass of the composition. When the content of the glycerin derivative-type surfactant exceeds 5% by mass, stickiness occurs.
- a skin external preparation composition is (C) hydrophilic surfactant, (C1) nonionic surfactant among glycerin derivative type surfactant and sorbitan derivative type surfactant. contains.
- the mass of the amphoteric surfactant is less than 0.5 times the mass of the (A) silicone elastomer, or the content of the (C2) amphoteric surfactant in the composition is less than 0.5% by mass, preferably The composition does not contain a substantial amount of (C2) amphoteric surfactant.
- the glycerin derivative type surfactant is preferably 0.2 parts by mass or more, more preferably 0.25 parts by mass or more, and 0.3 parts by mass or more with respect to 1 part by mass of the (A) silicone elastomer. More preferably, it is 0.35 parts by mass or more.
- the effect which suppresses aggregation of a silicone elastomer will fall that a glycerol derivative type surfactant is less than 0.2 mass part.
- the glycerin derivative-type surfactant can be 4 parts by mass or less, 3 parts by mass or less, 2.5 parts by mass or less, or 2 parts by mass or less based on 1 part by mass of the (A) silicone elastomer. When the glycerin derivative type surfactant exceeds 4 parts by mass, stickiness occurs when applied.
- the mass ratio of (A) silicone elastomer and (C2) amphoteric surfactant in the composition of the present disclosure is preferably 2 or more when the mass of (C2) is 1. The above is more preferable.
- the mass ratio of (A) silicone elastomer to (C2) amphoteric surfactant is preferably (A) of 7 or less, and (C2) of 1 or less when the mass of (C2) is 1. More preferably. When the mass ratio is within this range, aggregation of the silicone elastomer can be suppressed.
- the content of the amphoteric surfactant in the composition of the present disclosure is preferably 0.05% by mass or more and more preferably 0.1% by mass or more with respect to the mass of the composition.
- the content of the amphoteric surfactant is preferably 0.5% by mass or less and more preferably 0.4% by mass or less with respect to the mass of the composition.
- the content of the amphoteric surfactant exceeds 0.5% by mass, the emulsified particles are united and the emulsion stability is lowered.
- the glycerin derivative type surfactant is preferably less than 0.2 parts by mass with respect to 1 part by mass of the (C2) amphoteric surfactant. More preferably, it is 1 mass part or less, More preferably, it is 0.05 mass part or less, More preferably, it is 0 mass part.
- the glycerin derivative type surfactant is 0.2 parts by mass or more, (A) the silicone elastomer tends to aggregate.
- composition of the present disclosure will be described below with examples. However, the composition of the present disclosure is not limited to the following examples. Moreover, the composition of this indication is not limited to cosmetics.
- the unit of the content rate shown in each table is mass%.
- the evaluation items described in the table were evaluated based on the following criteria. The viscosity was measured at 30 ° C. using a BL type viscometer (No. 3 rotor, rotation speed: 12 rpm).
- the evaluation item “Elastomer dispersion stability (immediately after sample preparation)” in the table refers to the result of visual confirmation of the dispersibility (cohesiveness) of the silicone elastomer on the blackboard immediately after the composition was prepared.
- the evaluation item “Elastomer aggregation suppression (after rolling treatment)” described in the table refers to the result of visually confirming the dispersibility (aggregation property) of the silicone elastomer on the blackboard after rolling the composition.
- the rolling treatment refers to a treatment in which 30 ml of the composition is put into a 50 ml screw tube and the screw tube is rotated at 25 ° C. at a rotation speed of 45 rpm for 4 hours.
- compositions were prepared by varying the content of the silicone elastomer.
- compositions having the lipophilic surfactants listed in Table 3 added as the lipophilic surfactants of component (2) were prepared, and the dispersion stability of the silicone elastomer was observed.
- the results are shown in Table 3.
- the component (B ′) of Test Examples 7 and 9 to 12 is a polyglycerin surfactant.
- the component (B ′) of Test Example 8 is a pentaerythritol surfactant.
- the component (B ′) of Test Examples 13 to 15 is a polyether silicone surfactant.
- Test Examples 16 to 18 containing no silicone surfactant even if the content of the hydrophilic surfactant was varied, a little aggregation of the silicone elastomer was observed immediately after the preparation of the sample. Aggregation was observed.
- Test Examples 19 to 26 containing a silicone surfactant the viscosity was 5,000 mPa ⁇ s or less in Test Examples 19 to 21 and 24 to 26, and the viscosity was 8,500 mPa ⁇ s or less in Test Example 22. Even so, the dispersion stability of the silicone elastomer could be improved.
- the content of the silicone surfactant is preferably 0.3% by mass or more, more preferably 0.5% by mass or more, and more preferably 0.8% by mass or more.
- the content of the silicone surfactant is preferably 2.5% by mass or less, more preferably 2% by mass or less, and further preferably 1.5% by mass or less.
- the viscosity was not intentionally increased from that of the other test examples in order to suppress the aggregation of the silicone elastomer, but the viscosity was reduced because a W / O / W type multiple emulsified state was obtained. It is thought that it became high.
- the content of the silicone surfactant is preferably 5% by mass or less, more preferably 4% by mass or less, and further preferably 3% by mass or less.
- Test Examples 27 to 37 In Test Examples 27 to 37, the content of the hydrophilic surfactant was varied. Tables 6 and 7 show the compositions and results. In any of the test examples, the viscosity was 6,000 mPa ⁇ s or less, preferably 5,000 mPa ⁇ s or less, but the dispersion stability of the silicone elastomer immediately after preparation of the sample was good.
- the silicone surfactant has a high elastomer aggregation suppressing effect.
- the hydrophilic nonionic surfactants in addition to the component (3) which is a sorbitan derivative type surfactant, the component (4) which is a glycerin derivative type surfactant and / or a sterol derivative type surfactant.
- component (5) When component (5) was added, the effect of suppressing elastomer aggregation after the rolling treatment could be further enhanced. Therefore, in order to increase the effect of suppressing the aggregation of elastomer, the combination of sorbitan derivative type surfactant and glycerin derivative type surfactant is more effective for hydrophilic nonionic surfactant than sorbitan derivative type surfactant alone. It is thought that.
- hydrophilic nonionic surfactants other than sorbitan and glyceryl can be added.
- the glycerin derivative-type surfactant has a high elastomer aggregation suppressing effect.
- component (4) and / or (5) is preferably added in an amount of 0.4 mass% or more, more preferably 0.5 mass% or more.
- the component (6) which is an amphoteric surfactant
- the effect of suppressing elastomer aggregation after the rolling treatment could be further enhanced. From this, it is considered that a combination of a nonionic surfactant and an amphoteric surfactant is effective for suppressing aggregation of the elastomer.
- component (6) when component (6) is added, the emulsification stability tends to be improved, and the amphoteric surfactant is considered to have a high emulsification stability effect.
- the content of the amphoteric surfactant is preferably 0.1% by mass or more, more preferably 0.15% by mass or more, and further preferably 0.2% by mass or more.
- the mass of (C) is 1, the mass of (A) is preferably 0.2 or more, more preferably 0.3 or more, and even more preferably 0.5 or more. Get it.
- the mass of (C) is 1, the mass of (A) is preferably 2 or less, and more preferably 1.5 or less.
- the mass of (A) is 5.6 times the mass of (C2). Accordingly, when the mass of (C2) is 1, the mass of (A) is preferably 2 or more, and more preferably 3 or more. When the mass of (C2) is 1, the mass of (A) is preferably 7 or less, and more preferably 6.5 or less.
- the mass of the glycerin surfactant was 0.36 times the mass of (A). From this, when the mass of (A) is 1, the mass of the glycerin type surfactant is preferably 0.2 or more, and more preferably 0.3 or more. When the mass of (A) is 1, the mass of the glycerin surfactant is preferably 4 or less, and more preferably 3 or less.
- Test Examples 42 to 48 the content of component (5), which is an amphoteric surfactant, was changed. In Test Examples 42 and 43, no nonionic surfactant was added. In Test Examples 44 and 45, components (3) and (4), which are nonionic surfactants, were added. In Test Examples 46 to 48, component (4) which is a glycerin derivative type surfactant was added as a nonionic surfactant, but component (4) which was a sorbitan derivative type surfactant was not added. Tables 9 and 10 show the compositions and results.
- Test Examples 42 and 43 that do not contain a nonionic surfactant
- Test Example 42 in which the content of amphoteric surfactant is low, the evaluation after the rolling treatment was greatly reduced from the evaluation immediately after sample preparation.
- Test Example 43 having a high amphoteric surfactant content, aggregation due to the rolling treatment could be suppressed.
- Test Example 43 was able to improve the dispersion stability immediately after the preparation of the sample, compared with Test Example 42. Furthermore, the viscosity of Test Example 43 was lower than that of Test Example 42. From this, it was found that even if there is no nonionic surfactant, the amphoteric surfactant alone can enhance the dispersion stability and aggregation suppressing effect of the silicone elastomer.
- the content of the amphoteric surfactant is preferably 0.6% by mass or more, more preferably 0.7% by mass or more based on the mass of the composition. More preferably, the content is 0.8% by mass or more.
- Test Example 49 using a non-emulsifying silicone elastomer more than half of the panelists felt smooth and did not feel sticky.
- Test Example 50 using the emulsified silicone elastomer less than half of the panelists did not feel smooth and felt sticky. From this, in the composition of this indication, in order to obtain both a smooth use feeling and a non-sticky use feeling, it is thought that the non-emulsification type
- Examples of the formulation of the external composition for skin of the present disclosure are listed below.
- the application example of the external composition for skin of the present disclosure is not limited by the following formulation examples.
- the hydrophilic nonionic surfactant comprises polyoxyethylene glycerin ether and polyoxyethylene sorbitan fatty acid ester.
- the amphoteric surfactant comprises lauryldimethylamide acetic acid betaine.
- the external composition for skin further contains silicone oil.
- the average particle size of the silicone elastomer is 100 ⁇ m or less.
- the external composition for skin further contains a polymer and / or copolymer (including a crosslinked polymer) having 2-acrylamido-2-propanesulfonic acid or a salt thereof as a structural unit.
- the external composition for skin is an oil-in-water cosmetic.
- composition of the present disclosure can be suitably used for a cosmetic applied to the skin.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Description
シリコーンエラストマーとしては、例えば、シリコーンエラストマー(オルガノポリシロキサン)が挙げられる。シリコーンエラストマーには、例えば、シリコーンポリマーが三次元的に架橋した架橋型シリコーン(架橋型オルガノポリシロキサン)が含まれる。シリコーンエラストマーは、非乳化型シリコーンエラストマーであると好ましい。本開示において非乳化型シリコーンエラストマーとは、架橋部又は主鎖がポリオキシアルキレン基で修飾されていないシリコーンエラストマーのことをいう。特に、非乳化型シリコーンエラストマーは、疎水部からなる(親水部を有さない)と好ましい。ポリオキシアルキレン基を有する乳化型シリコーンエラストマーを添加すると、界面活性剤のようなべたつきが生じ、組成物を肌へ塗布する際のなめらかさが失われてしまう。一方、非乳化型シリコーンエラストマーを用いると、べたつきを抑制すると共に、肌への塗布時のなめらかさ(スベスベ感)を得ることができる。
シリコーン界面活性剤は、ポリエーテル変性シリコーン界面活性剤であると好ましい。ポリエーテル変性シリコーン界面活性剤としては、例えば、シリコーン骨格に、ポリオキシエチレン(POE)やポリオキシプロピレン(POP)等のポリオキシアルキレン基を導入したポリエーテル変性シリコーンを用いることができる。このうち、特に、シリコーン界面活性剤は、シリコーン鎖(シロキサン鎖)を主鎖として有し、ポリエーテル基を有する親水基を側鎖として有すると好ましい。シリコーン界面活性剤は、シリコーン鎖に複数のポリオキシアルキレン基(ポリエーテル鎖)を側鎖として導入したペンダント型(櫛型)構造を有すると好ましい。シリコーン界面活性剤がペンダント型構造を有すると、シリコーンエラストマーの分散安定性をより高めることができる。
親水性界面活性剤としては、非イオン性界面活性剤及び/又は両性界面活性剤を使用することができる。
親水性非イオン界面活性剤としては、例えば、POE-ソルビタン脂肪酸エステル(例えば、POE-ソルビタンモノオレエート、POE-ソルビタンモノステアレート、POE-ソルビタンモノオレエート、POE-ソルビタンテトラオレエート等);POE-ソルビット脂肪酸エステル(例えば、POE-ソルビットモノラウレート、POE-ソルビットモノオレエート、POE-ソルビットペンタオレエート、POE-ソルビットモノステアレート等);POE-グリセリン脂肪酸エステル(例えば、POE-グリセリンモノステアレート、POE-グリセリンモノイソステアレート、POE-グリセリントリイソステアレート等のPOE-モノオレエート等);POE-脂肪酸エステル(例えば、POE-ジステアレート、POE-モノジオレエート、ジステアリン酸エチレングリコール等);POE-アルキルエーテル(例えば、POE-ラウリルエーテル、POE-オレイルエーテル、POE-ステアリルエーテル、POE-ベヘニルエーテル、POE-2-オクチルドデシルエーテル、POE-コレスタノールエーテル等);プルロニック型(例えば、プルロニック等);POE・POP-アルキルエーテル(例えば、POE・POP-セチルエーテル、POE・POP-2-デシルテトラデシルエーテル、POE・POP-モノブチルエーテル、POE・POP-水添ラノリン、POE・POP-グリセリンエーテル等);テトラPOE・テトラPOP-エチレンジアミン縮合物(例えば、テトロニック等);POE-ヒマシ油硬化ヒマシ油誘導体(例えば、POE-ヒマシ油、POE-硬化ヒマシ油、POE-硬化ヒマシ油モノイソステアレート、POE-硬化ヒマシ油トリイソステアレート、POE-硬化ヒマシ油モノピログルタミン酸モノイソステアリン酸ジエステル、POE-硬化ヒマシ油マレイン酸等);POE-ミツロウ・ラノリン誘導体(例えば、POE-ソルビットミツロウ等);アルカノールアミド(例えば、ヤシ油脂肪酸ジエタノールアミド、ラウリン酸モノエタノールアミド、脂肪酸イソプロパノールアミド等);POE-プロピレングリコール脂肪酸エステル;POE-アルキルアミン;POE-脂肪酸アミド;ショ糖脂肪酸エステル;アルキルエトキシジメチルアミンオキシド;トリオレイルリン酸等が挙げられる。
両性界面活性剤としては、例えば、イミダゾリン系両性界面活性剤(例えば、2-ウンデシル-N,N,N-(ヒドロキシエチルカルボキシメチル)-2-イミダゾリンナトリウム、2-ココイル-2-イミダゾリニウムヒドロキサイド-1-カルボキシエチロキシ2ナトリウム塩等);ベタイン系界面活性剤(例えば、2-ヘプタデシル-N-カルボキシメチル-N-ヒドロキシエチルイミダゾリニウムベタイン、ラウリルジメチルアミノ酢酸ベタイン、アルキルベタイン、アミドベタイン、スルホベタイン等)等が挙げられる。
本開示の組成物は、上記成分に加えて、(D)シリコーン油をさらに含むことができる。
本開示の組成物は、上記成分に加えて、(E)増粘剤をさらに含むことができる。
本開示の化粧料組成物は、本開示の効果を阻害しない範囲において、他の成分、例えば、水性溶媒、アニオン性界面活性剤、カチオン界面活性剤、親油性非イオン性界面活性剤、粉体、保湿剤、水溶性高分子、増粘剤、油性成分、皮膜剤、紫外線吸収剤、金属イオン封鎖剤、アミノ酸、有機アミン、高分子エマルジョン、pH調整剤、皮膚栄養剤、ビタミン、酸化防止剤、酸化防止助剤、香料等を必要に応じて適宜含有することができる。
第1実施形態においては、皮膚外用剤組成物は、(C)親水性界面活性剤として、(C1)非イオン性界面活性剤のうち、グリセリン誘導体型界面活性剤を含有し、ソルビタン誘導体型界面活性剤を含有していない。両性界面活性剤の質量が(A)シリコーンエラストマーの質量の0.5倍未満であるか、又は組成物における(C2)両性界面活性剤の含有率は0.5質量%未満であり、好ましくは、組成物は(C2)両性界面活性剤を実質量含有していない。
第2実施形態においては、皮膚外用剤組成物は、(C)親水性界面活性剤として、(C1)非イオン性界面活性剤のうち、グリセリン誘導体型界面活性剤及びソルビタン誘導体型界面活性剤を含有する。両性界面活性剤の質量が(A)シリコーンエラストマーの質量の0.5倍未満であるか、又は組成物における(C2)両性界面活性剤の含有率は0.5質量%未満であり、好ましくは、組成物は(C2)両性界面活性剤を実質量含有していない。
第3実施形態においては、皮膚外用剤組成物は、(C)親水性界面活性剤として、(C1)非イオン性界面活性剤のうちグリセリン誘導体型界面活性剤及びソルビタン誘導体型界面活性剤を含有すると共に、(C2)両性界面活性剤を含有する。
第4実施形態においては、皮膚外用剤組成物は、(C)親水性界面活性剤として、(C2)両性界面活性剤を含有し、(C1)非イオン性界面活性剤を実質量含有していない。
A:シリコーンエラストマーの凝集は観察されなかった。
B:シリコーンエラストマーの凝集はほとんど観察されなかった。
C:シリコーンエラストマーの凝集が僅かに観察された。
D:シリコーンエラストマーの凝集が少し観察された。
E:シリコーンエラストマーの凝集が観察された。
A:乳化粒子の合一は観察されなかった。
B:乳化粒子が経時的に僅かに合一した。
C:乳化粒子が経時的に合一した。
D:試料作製直後から油分が浮いた状態となった。
シリコーンエラストマーの含有率を変動させて組成物を作製した。
下記表2の組成において、成分(2)の親油性界面活性剤として、表3に挙げた親油性界面活性剤を添加した組成物をそれぞれ作製し、シリコーンエラストマーの分散安定性を観察した。結果を表3に示す。試験例7及び9~12の成分(B’)はポリグリセリン系界面活性剤である。試験例8の成分(B’)はペンタエリスリトール系界面活性剤である。試験例13~15の成分(B’)がポリエーテルシリコーン界面活性剤である。
試験例16~26においては、成分(2)シリコーン界面活性剤の含有率を変動させた。試験例16~18においては、シリコーン界面活性剤を添加させないことに加えて、成分(6)親水性界面活性剤の含有率を変動させた。表4及び表5に、組成及び結果を示す。
試験例27~37においては、親水性界面活性剤の含有率を変動させた。表6及び表7に、組成及び結果を示す。いずれの試験例においても、粘度6,000mPa・s以下、好ましくは5,000mPa・s以下という低粘度であったが、試料作製直後のシリコーンエラストマーの分散安定性は良好であった。
試験例38~41においては、親水性非イオン性界面活性剤として、ソルビタン誘導体型界面活性剤を添加せずに、グリセリン誘導体型界面活性剤である成分(3)を添加した組成物を作製し、成分(3)の含有率を変化させた。両性界面活性剤は添加していない。表8に、組成及び結果を示す。
試験例42~48においては、両性界面活性剤である成分(5)の含有率を変化させた。試験例42及び43においては非イオン性界面活性剤を添加しなかった。試験例44及び45においては非イオン性界面活性剤である成分(3)及び(4)を添加した。試験例46~48においては非イオン性界面活性剤としてグリセリン誘導体型界面活性剤である成分(4)を添加したが、ソルビタン誘導体型界面活性剤である成分(4)は添加しなかった。表9及び表10に、組成及び結果を示す。
試験例49~50においては、非乳化型シリコーンエラストマーと乳化型シリコーンエラストマーの使用感を比較した。試験例50において使用した成分(A)のシリコーンエラストマーは、シリコーン鎖を親水基であるポリグリセリン鎖(ポリエーテル鎖)で架橋した乳化型架橋型オルガノポリシロキサンである。一方、試験例49において使用した成分(A)のシリコーンエラストマーは、シリコーン鎖を疎水基で架橋した非乳化型架橋型オルガノポリシロキサンである。
A:組成物を塗布しているとき、塗布のなめらかさを感じたパネラーが10名以上;
B:組成物を塗布しているとき、塗布のなめらかさを感じたパネラーが10名未満。
[使用感(べたつきのなさ)]
A:組成物を塗布しているとき、塗布のべたつきを感じなかったパネラーが10名以上;
B:組成物を塗布しているとき、塗布のべたつきを感じなかったパネラーが10名未満。
[付記1]
本開示の皮膚外用組成物は、シリコーンエラストマーと、ポリエーテル変性シリコーン界面活性剤と、親水性非イオン性界面活性剤及び/又は両性界面活性剤と、を含有する。組成物の粘度は、9,500mPa・s以下である。
[付記2]
0.1質量%~8質量%のシリコーンエラストマーと、
ポリエーテル変性シリコーン界面活性剤と、
親水性非イオン性界面活性剤と、を含有し、
前記親水性非イオン性界面活性剤がグリセリン誘導体型界面活性剤を含み、
前記シリコーンエラストマー1質量部に対して前記ポリエーテル変性シリコーン界面活性剤は0.3質量部以上であり、
前記シリコーンエラストマー1質量部に対して前記グリセリン誘導体型界面活性剤は0.2質量部以上であり、
粘度が9,500mPa・s以下である、皮膚外用組成物。
[付記3]
0.1質量%~8質量%のシリコーンエラストマーと、
ポリエーテル変性シリコーン界面活性剤と、
両性界面活性剤と、を含有し、
前記シリコーンエラストマー1質量部に対して前記ポリエーテル変性シリコーン界面活性剤は0.3質量部以上であり、
前記シリコーンエラストマー1質量部に対して前記両性界面活性剤は0.6質量部より多く、好ましくは0.65質量部以上、より好ましくは0.7質量部以上であり、
グリセリン誘導体型親水性非イオン性界面活性剤を実質量含有せず、
粘度が9,500mPa・s以下である、皮膚外用組成物。
[付記4]
好ましい形態によれば、シリコーンエラストマーの含有率が組成物の質量に対して0.1質量%~8質量%である。
[付記5]
好ましい形態によれば、ポリエーテル変性シリコーン界面活性剤は、ポリエーテル基を有する複数の親水基が主鎖からグラフトした構造を有する。
[付記6]
好ましい形態によれば、主鎖はシリコーン鎖を含む。
[付記7]
好ましい形態によれば、ポリエーテル変性シリコーン界面活性剤は、ポリオキシエチレンメチルポリシロキサン共重合体を含む。
[付記8]
好ましい形態によれば、シリコーンエラストマーとポリエーテル変性シリコーン界面活性剤との質量比は、シリコーンエラストマー:ポリエーテル変性シリコーン界面活性剤=0.4:1~3:1である。
[付記9]
好ましい形態によれば、親水性非イオン性界面活性剤は、ポリオキシエチレングリセリンエーテルを含む。
[付記10]
好ましい形態によれば、シリコーンエラストマーと親水性非イオン性界面活性剤との質量比は、シリコーンエラストマー:親水性非イオン性界面活性剤=0.2:1~3:1である。
[付記11]
好ましい形態によれば、親水性非イオン性界面活性剤は、ポリオキシエチレングリセリンエーテル及びポリオキシエチレンソルビタン脂肪酸エステルを含む。ポリオキシエチレングリセリンエーテルとポリオキシエチレンソルビタン脂肪酸エステルとの質量比は、ポリオキシエチレングリセリンエーテル:ポリオキシエチレンソルビタン脂肪酸エステル=1:0.5~1:3である。
[付記12]
好ましい形態によれば、両性界面活性剤は、ラウリルジメチルアミド酢酸ベタインを含む。
[付記13]
好ましい形態によれば、シリコーンエラストマーと両性界面活性剤との質量比は、シリコーンエラストマー:両性界面活性剤=2:1~7:1である。
[付記14]
好ましい形態によれば、皮膚外用組成物は、シリコーン油をさらに含有する。
[付記15]
好ましい形態によれば、シリコーンエラストマーの平均粒径は100μm以下である。
[付記16]
好ましい形態によれば、皮膚外用組成物は、2-アクリルアミド-2-プロパンスルホン酸又はその塩を構成単位として有する重合体及び/又は共重合体(架橋重合体含む)をさらに含有する。
[付記17]
好ましい形態によれば、皮膚外用組成物は、水中油型化粧料である。
Claims (18)
- 0.1質量%~8質量%の非乳化型シリコーンエラストマーと、
ポリエーテル変性シリコーン界面活性剤と、
親水性非イオン性界面活性剤と、を含有し、
前記親水性非イオン性界面活性剤がグリセリン誘導体型界面活性剤を含み、
前記シリコーンエラストマー1質量部に対して前記ポリエーテル変性シリコーン界面活性剤は0.3質量部以上であり、
前記シリコーンエラストマー1質量部に対して前記グリセリン誘導体型界面活性剤は0.2質量部以上であり、
両性界面活性剤を含有する場合には、前記両性界面活性剤は前記グリセリン誘導体型界面活性剤1質量部に対して1.5質量部以下であり、
粘度が9,500mPa・s以下である、皮膚外用組成物。 - 前記両性界面活性剤を含有する場合、前記グリセリン誘導体型界面活性剤1質量部に対して前記両性界面活性剤は0.15質量部~1.5質量部である、請求項1に記載の皮膚外用組成物。
- 0.1質量%~8質量%の非乳化型シリコーンエラストマーと、
ポリエーテル変性シリコーン界面活性剤と、
両性界面活性剤と、を含有し、
前記シリコーンエラストマー1質量部に対して前記ポリエーテル変性シリコーン界面活性剤は0.3質量部以上であり、
前記シリコーンエラストマー1質量部に対して前記両性界面活性剤は0.65質量部以上であり、
グリセリン誘導体型親水性非イオン性界面活性剤を含有する場合には、前記グリセリン誘導体型界面活性剤は前記両性界面活性剤1質量部に対して0.2質量部未満であり、
粘度が9,500mPa・s以下である、皮膚外用組成物。 - 前記両性界面活性剤は、ラウリルジメチルアミド酢酸ベタインを含む、請求項2又は3に記載の皮膚外用組成物。
- 前記ポリエーテル変性シリコーン界面活性剤は、ポリエーテル基を有する複数の親水基が主鎖からグラフトした構造を有する、請求項1~4のいずれか一項に記載の皮膚外用組成物。
- 前記主鎖はシリコーン鎖を含む、請求項5に記載の皮膚外用組成物。
- 前記ポリエーテル変性シリコーン界面活性剤は、ポリオキシエチレンメチルポリシロキサン共重合体を含む、請求項1~6のいずれか一項に記載の皮膚外用組成物。
- 前記グリセリン誘導体型界面活性剤はポリオキシエチレングリセリン脂肪酸エステルを含む、請求項1~7のいずれか一項に記載の皮膚外用組成物。
- 前記親水性非イオン性界面活性剤は、ソルビタン誘導体型界面活性剤をさらに含み、
前記グリセリン誘導体型界面活性剤1質量部に対して前記ソルビタン誘導体型界面活性剤は0.5質量部~5質量部である、請求項1~8のいずれか一項に記載の皮膚外用組成物。 - シリコーン油をさらに含有する、請求項1~9のいずれか一項に記載の皮膚外用組成物。
- 前記シリコーンエラストマーの平均粒径は100μm以下である、請求項1~10のいずれか一項に記載の皮膚外用組成物。
- 2-アクリルアミド-2-プロパンスルホン酸又はその塩を構成単位として有する重合体及び/又は共重合体(架橋重合体含む)をさらに含有する、請求項1~11のいずれか一項に記載の皮膚外用組成物。
- 前記シリコーンエラストマーの含有率は、前記組成物の質量に対して5質量%以下である、請求項1~12のいずれか一項に記載の皮膚外用組成物。
- 前記シリコーンエラストマー1質量部に対して前記ポリエーテル変性シリコーン界面活性剤は0.5質量部以上である、請求項1~13のいずれか一項に記載の皮膚外用組成物。
- 前記シリコーンエラストマーは、ポリオキシアルキレン基を有さない架橋型オルガノポリシロキサンである、請求項1~14のいずれか一項に記載の皮膚外用組成物。
- 前記シリコーンエラストマーは不定形状の粒子の形態を有する、請求項1~15のいずれか一項に記載の皮膚外用組成物。
- 前記シリコーンエラストマーはゲル状である、請求項1~16のいずれか一項に記載の皮膚外用組成物。
- 水中油型化粧料である、請求項1~17のいずれか一項に記載の皮膚外用組成物。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020197016423A KR102477212B1 (ko) | 2016-11-14 | 2017-11-14 | 피부 외용제 조성물 |
EP17869733.0A EP3539532B1 (en) | 2016-11-14 | 2017-11-14 | Skin care composition |
CN201780070074.4A CN109922788B (zh) | 2016-11-14 | 2017-11-14 | 皮肤外用剂组合物 |
US16/349,128 US20190269605A1 (en) | 2016-11-14 | 2017-11-14 | Skin care composition |
JP2018550306A JP7076373B2 (ja) | 2016-11-14 | 2017-11-14 | 皮膚外用剤組成物 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016221654 | 2016-11-14 | ||
JP2016-221654 | 2016-11-14 | ||
JP2017-168872 | 2017-09-01 | ||
JP2017168872 | 2017-09-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018088570A1 true WO2018088570A1 (ja) | 2018-05-17 |
Family
ID=62109267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/040974 WO2018088570A1 (ja) | 2016-11-14 | 2017-11-14 | 皮膚外用剤組成物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20190269605A1 (ja) |
EP (1) | EP3539532B1 (ja) |
JP (1) | JP7076373B2 (ja) |
KR (1) | KR102477212B1 (ja) |
CN (1) | CN109922788B (ja) |
TW (1) | TW201825072A (ja) |
WO (1) | WO2018088570A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020027164A1 (ja) * | 2018-08-01 | 2020-02-06 | 株式会社 資生堂 | 水中油型乳化化粧料 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7114164B2 (ja) * | 2017-08-07 | 2022-08-08 | 株式会社 資生堂 | 粉体含有水系組成物及び皮膚外用剤 |
IT201900021792A1 (it) * | 2019-11-21 | 2021-05-21 | Chromavis Spa | Una composizione cosmetica e un prodotto per il trucco comprendente tale composizione cosmetica |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006213730A (ja) | 2006-04-28 | 2006-08-17 | Shin Etsu Chem Co Ltd | 化粧料 |
JP2011513463A (ja) * | 2008-03-10 | 2011-04-28 | シャネル パフュームズ ビューテ | 油中水型乳化化粧料組成物 |
JP2011149017A (ja) * | 2009-12-24 | 2011-08-04 | Dow Corning Toray Co Ltd | カルボシロキサンデンドリマー構造を有する共重合体、並びに、それを含む組成物及び化粧料 |
JP2013082686A (ja) | 2011-09-27 | 2013-05-09 | Shiseido Co Ltd | 水中油型乳化皮膚外用剤 |
JP2014024834A (ja) * | 2012-06-22 | 2014-02-06 | Mitsubishi Pencil Co Ltd | 高内水相油中水型乳化化粧料 |
JP2014108934A (ja) * | 2012-11-30 | 2014-06-12 | Naris Cosmetics Co Ltd | 紫外線吸収剤含有皮膚外用剤 |
JP2015030705A (ja) * | 2013-08-02 | 2015-02-16 | 富士フイルム株式会社 | セラミド分散組成物 |
JP2015218113A (ja) * | 2014-05-14 | 2015-12-07 | 株式会社 資生堂 | うるおい補給用スティック状化粧料 |
WO2016052277A1 (ja) * | 2014-09-30 | 2016-04-07 | 株式会社マンダム | 乳化デオドラント組成物およびデオドラント剤 |
JP2017178806A (ja) * | 2016-03-29 | 2017-10-05 | 株式会社マンダム | 乳化保湿化粧料およびその使用方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1602352B1 (en) * | 2004-05-24 | 2013-03-06 | The Procter & Gamble Company | Cosmetic foundation comprising cross-linked, non-emulsifying organopolysiloxane elastomer |
US20110123579A1 (en) * | 2005-05-12 | 2011-05-26 | Fatemeh Mohammadi | Cosmetic Composition For Diminishing The Appearance Of Lines And Pores |
JP5026729B2 (ja) * | 2006-04-12 | 2012-09-19 | 花王株式会社 | W/o/w型乳化組成物 |
JP5532845B2 (ja) * | 2009-11-18 | 2014-06-25 | 信越化学工業株式会社 | 化粧料 |
JP5174789B2 (ja) * | 2009-11-25 | 2013-04-03 | 花王株式会社 | O/w型乳化化粧料 |
JP5373046B2 (ja) * | 2011-12-19 | 2013-12-18 | 株式会社 資生堂 | 水中油型乳化組成物 |
JP5894434B2 (ja) * | 2011-12-28 | 2016-03-30 | 花王株式会社 | 表面処理粉体及び化粧料の製造方法 |
-
2017
- 2017-11-14 EP EP17869733.0A patent/EP3539532B1/en active Active
- 2017-11-14 CN CN201780070074.4A patent/CN109922788B/zh active Active
- 2017-11-14 JP JP2018550306A patent/JP7076373B2/ja active Active
- 2017-11-14 US US16/349,128 patent/US20190269605A1/en not_active Abandoned
- 2017-11-14 TW TW106139580A patent/TW201825072A/zh unknown
- 2017-11-14 KR KR1020197016423A patent/KR102477212B1/ko active IP Right Grant
- 2017-11-14 WO PCT/JP2017/040974 patent/WO2018088570A1/ja active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006213730A (ja) | 2006-04-28 | 2006-08-17 | Shin Etsu Chem Co Ltd | 化粧料 |
JP2011513463A (ja) * | 2008-03-10 | 2011-04-28 | シャネル パフュームズ ビューテ | 油中水型乳化化粧料組成物 |
JP2011149017A (ja) * | 2009-12-24 | 2011-08-04 | Dow Corning Toray Co Ltd | カルボシロキサンデンドリマー構造を有する共重合体、並びに、それを含む組成物及び化粧料 |
JP2013082686A (ja) | 2011-09-27 | 2013-05-09 | Shiseido Co Ltd | 水中油型乳化皮膚外用剤 |
JP2014024834A (ja) * | 2012-06-22 | 2014-02-06 | Mitsubishi Pencil Co Ltd | 高内水相油中水型乳化化粧料 |
JP2014108934A (ja) * | 2012-11-30 | 2014-06-12 | Naris Cosmetics Co Ltd | 紫外線吸収剤含有皮膚外用剤 |
JP2015030705A (ja) * | 2013-08-02 | 2015-02-16 | 富士フイルム株式会社 | セラミド分散組成物 |
JP2015218113A (ja) * | 2014-05-14 | 2015-12-07 | 株式会社 資生堂 | うるおい補給用スティック状化粧料 |
WO2016052277A1 (ja) * | 2014-09-30 | 2016-04-07 | 株式会社マンダム | 乳化デオドラント組成物およびデオドラント剤 |
JP2017178806A (ja) * | 2016-03-29 | 2017-10-05 | 株式会社マンダム | 乳化保湿化粧料およびその使用方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3539532A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020027164A1 (ja) * | 2018-08-01 | 2020-02-06 | 株式会社 資生堂 | 水中油型乳化化粧料 |
Also Published As
Publication number | Publication date |
---|---|
CN109922788A (zh) | 2019-06-21 |
JPWO2018088570A1 (ja) | 2019-10-10 |
US20190269605A1 (en) | 2019-09-05 |
KR102477212B1 (ko) | 2022-12-12 |
EP3539532A4 (en) | 2020-06-24 |
EP3539532B1 (en) | 2022-09-14 |
KR20190084277A (ko) | 2019-07-16 |
JP7076373B2 (ja) | 2022-05-27 |
CN109922788B (zh) | 2022-04-08 |
TW201825072A (zh) | 2018-07-16 |
EP3539532A1 (en) | 2019-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5972437B2 (ja) | 固形粉末化粧料の製造方法 | |
JP5277011B2 (ja) | 水中油型乳化白濁皮膚化粧料 | |
WO2018110659A1 (ja) | 水中油型組成物 | |
JP7198760B2 (ja) | 非水系用増粘剤及び増粘組成物 | |
WO2018074149A1 (ja) | 洗浄剤組成物 | |
JP2010024159A (ja) | 微細エマルション組成物、およびその製造方法 | |
WO2018088570A1 (ja) | 皮膚外用剤組成物 | |
WO2018079717A1 (ja) | 水中油型皮膚外用組成物 | |
JP2010024161A (ja) | 微細エマルション組成物、およびその製造方法 | |
JP2009227645A (ja) | 皮膚外用剤 | |
JP7114164B2 (ja) | 粉体含有水系組成物及び皮膚外用剤 | |
JP7169879B2 (ja) | 整髪料組成物 | |
JP2019218307A (ja) | 組成物 | |
JP4349883B2 (ja) | 皮膚外用組成物 | |
US20220040060A1 (en) | Water-in-oil composition for external application to skin | |
JP2006045133A (ja) | 水中油型乳化組成物 | |
JP2010024160A (ja) | 微細エマルション組成物、およびその製造方法 | |
WO2022085562A1 (ja) | 油中水型組成物 | |
JP4301499B2 (ja) | 皮膚外用組成物 | |
WO2020116487A1 (ja) | 乳化型化粧料組成物 | |
WO2011102526A1 (ja) | 化粧料 | |
JP2013032294A (ja) | 化粧料 | |
JP2006188448A (ja) | 皮膚外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17869733 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018550306 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20197016423 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2017869733 Country of ref document: EP |